OOIR: Observatory of International Research

Papers

(The TQCC of JAMA Psychiatry is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Combination Antidepressant Therapy vs Monotherapy—Further Considerations	637
Potential Limitations for Assessing Adverse Posttraumatic Neuropsychiatric Sequelae With Wrist-Wearable Device and Self-report Survey	604
Assumptions and Limitations of the Synthetic Control Method	360
Error in Results	281
JAMA Psychiatry	235
JAMA Psychiatry	235
JAMA Psychiatry	235
The Reliability of Traumatic and Adverse Experiences	214
Diagnosing and Treating ADHD in Adults	177
Overmystifying the Psychedelic Experience	174
Magnetic Seizure Therapy vs Electroconvulsive Therapy for Major Depressive Episode	169
Error in Abstract	161
Managerial and Organizational Challenges in the Age of AI	156
Consistency of Delusion Themes Across First and Subsequent Episodes of Psychosis	150
Stop Counting Conversions—The Clinical High Risk for Psychosis Field Needs a New North Star	150
An Opportunity to Advance Cannabis Science—DEA Rescheduling	145
Neighborhood Disadvantage and Autism Spectrum Disorder in a Population With Health Insurance	142
Brief Cognitive Behavioral Therapy for Suicidal Military Personnel and Veterans	140
Social Vulnerability and Prevalence and Treatment for Mental Health and Substance Use Disorders	140
Issues in Clinical Trial Design—Lessons From the FDA’s Rejection of MDMA	135
Integrating Financing Variables Into Behavioral Health Policy Implementation Research	134
Prenatal Adversities and Risk of Persistent Youth Psychopathology and Altered Cortical Thinning	134
TikTok Challenges—Unintentional Injuries vs Suicide Attempts	130
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder	129
Accelerated Theta-Burst Stimulation for Treatment-Resistant Depression	129

Polygenic Contributions to Lithium Augmentation Outcomes in Unipolar Depression	125
Patients Use AI—Clinicians Should Ask How	124
Left Ventrolateral Prefrontal Cortical Activity During Reward Expectancy and Mania Risk	121
Associations Between Objective and Subjective Experiences of Childhood Maltreatment and the Course of Emotional Disorders in Adulthood	116
JAMA Network Call for Papers on Health and the 2024 US Election	110
JAMA Psychiatry	109
Error in the Caption of Figures 2, 3, 4, and 5 and in Supplement 1	107
Error in Byline	106
Perinatal Mental Health Outcomes Following Natural Disasters	105
Addiction Medicine Physicians and Medicinal Cannabinoids	101
Searching the Brain for the Cause of Psychosis	99
US Veterans Affairs and Department of Defense 2023 Clinical Guideline for PTSD—Devolving Not Evolving	97
Risk for Mood, Anxiety, and Psychotic Disorders in Individuals at High and Low Genetic Liability for Bipolar Disorder and Major Depression	97
Serotonin 4 Receptor Brain Binding in Major Depressive Disorder and Association With Memory Dysfunction	97
Evaluation of Post–COVID-19 Cognitive Dysfunction: Recommendations for Researchers	96
Effect of a Tobacco Cessation Intervention Incorporating Weight Management for Adults With Serious Mental Illness	95
Semaglutide in Schizophrenia—A Top Clinical Trial	92
Military Sexual Trauma in the United States	87
Adolescent Mental Health Care and Stigma	87
Women With Schizophrenia—Ignored and Aging	84
Electroencephalography Microstate Instability and Clinical Outcomes in Individuals at Clinical High Risk of Psychosis	82
Association of Frailty With Risk of Suicide Attempt in a National Cohort of US Veterans Aged 65 Years or Older	80
Mental Health Impairment and Outpatient Mental Health Care of US Children and Adolescents	80
Living Alone and Drug Overdose Deaths in the US	79
Hyperalgesia in Patients With a History of Opioid Use Disorder	78
The Role of Energy Homeostasis in Depression Pathophysiology and Its Heterogeneity	78
COVID-19 and Mental Health in Young People—Causality or Co-occurrence?	76
Etiologic Studies of Premenstrual Disorders Require Prospective Confirmation of Affective Cyclicity	75
JAMA Psychiatry	73
Evaluation of a Model to Target High-risk Psychiatric Inpatients for an Intensive Postdischarge Suicide Prevention Intervention	72
Limitations for Assessing Optimism and Physical Functioning in Women—Reply	72
Combination Antidepressant Therapy vs Monotherapy—Further Considerations	72
Methadone-Involved Overdose Deaths in the US Before and After Federal Policy Changes Expanding Take-Home Methadone Doses From Opioid Treatment Programs	71
Toward a Pluralistic Model for the Schizophrenia Spectrum—Dopamine and Beyond	71
Measures of General Intelligence and Risk for Alcohol Use Disorder	70
Physician Suicide and Associated Features—What Defines a Physician?	70
JAMA Psychiatry	70
Does Vaccination Really Mitigate Psychiatric Implications of COVID-19?—Reply	70
Implementation Strategies Used and Reported in Brief Suicide Prevention Intervention Studies	69
Adjuvant Psychotherapies to Prevent Relapse in Bipolar Disorder	67
Neurobiological, Psychosocial, and Behavioral Mechanisms Mediating Associations Between Physical Activity and Psychiatric Symptoms in Youth in the Netherlands	66
Trends in Outpatient Psychotherapy Among Adults in the US	66
War Exposure and DNA Methylation in Syrian Refugee Children and Adolescents	66
Neurometabolites and Antipsychotic Response in Psychosis	65
Psychosis Spectrum Symptoms Before and After Adolescent Cannabis Use Initiation	64
Metabolomic Biomarker Signatures for Bipolar and Unipolar Depression	63
Sweetened Beverages and Incident All-Cause Dementia Among Older Adults	61
Genetic Liabilities Differentiating Bipolar Disorder, Schizophrenia, and Major Depressive Disorder, and Phenotypic Heterogeneity in Bipolar Disorder	61
Social Determinants of Health and Suicide-Related Outcomes	60
Error in Figure 2	59

Errors in Author Affiliations, Table, and Figure 3	57
Etiologic Studies of Premenstrual Disorders Require Prospective Confirmation of Affective Cyclicity—Reply	57
Errors in Text, Tables, and Figure	57
Written Exposure Therapy Finds Solid Footing Alongside First-Line Psychotherapies for Posttraumatic Stress Disorder	57
Suicide Risk—A Specific Intervention Target	57
Reducing the Risks of Nuclear War	57
Rural and Urban Trends in Mental Health Readmissions	56
Ultrarare Coding Variants and Cognitive Function in Schizophrenia	56
Hospitalization Associated With Comorbid Psychiatric and Substance Use Disorders Among Adults With COVID-19 Treated in US Emergency Departments From April 2020 to August 2021	56
Treating Bipolar Depression Using Psilocybin—Validity Threats Regarding Efficacy and Safety	56
JAMA Psychiatry	56
GLP-1 Receptor Agonists for Pharmacologically Induced Weight Gain	55
A Case for Permanent Adoption of Expanded Telehealth Services and Prescribing Flexibilities for Opioid Use Disorder	55
A New CMS Payment Model for AI-Delivered Behavioral Health Care	54
Genetic and Phenotypic Features of Schizophrenia in the UK Biobank	54
All-Cause and Cause-Specific Mortality Among Individuals With Hypochondriasis	53
Brexpiprazole and Sertraline Combination Treatment in Posttraumatic Stress Disorder	53
Social Determinants of Health and Neurobiology Across the Schizophrenia Course	53
Assessment of Disruptive Life Events for Individuals Diagnosed With Schizophrenia or Bipolar I Disorder Using Data From a Consumer Credit Reporting Agency	53
Emotional Experience of People With Schizophrenia and People at Risk for Psychosis	50
A Closer Look at Ketogenic Diet Effects in Depression	50
Lifetime Suicide Attempts in Otherwise Psychiatrically Healthy Individuals	49
Preponderance of 9-Item Patient Health Questionnaire (PHQ-9) Evidence	49
Association of Receipt of Opioid Use Disorder–Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19	48
Racial and Ethnic Disparities in Buprenorphine Treatment Duration in the US	48
The Need for Functional Assessments in School-Based Mental Health Intervention Research	48
Brief Cognitive Behavioral Therapy for Suicidal Inpatients	48
Psychomotor Slowing in Psychosis and Inhibitory Repetitive Transcranial Magnetic Stimulation	47
Loss of PTSD Diagnosis in Response to Evidence-Based Treatments	47
Baseline Antipsychotic Dose and Transition to Psychosis in Individuals at Clinical High Risk	46
Bright Light Therapy as Add-On to Inpatient Treatment in Youth With Moderate to Severe Depression	46
Prospective and Retrospective Measures of Child Maltreatment and Their Association With Psychopathology	45
Sex Differences in Autism Heritability and Likelihood	44
Association of Ambient Temperature With the Prevalence of Intimate Partner Violence Among Partnered Women in Low- and Middle-Income South Asian Countries	44
Effect of General Practitioner Training in a Collaborative Child Mental Health Care Program on Children’s Mental Health Outcomes in a Low-Resource Setting	44
Cognitive Behavior Therapy for Mental Disorders in Adults	44
Time to Treat the Climate and Nature Crisis as One Indivisible Global Health Emergency	44
JAMA Psychiatry	44
Errors in Results and Tables	44
JAMA Psychiatry	44
Error in Title of Figure 1	44
JAMA Psychiatry—The Year in Review 2024	44
Striatal Activity to Reward Anticipation as a Moderator of the Association Between Early Behavioral Inhibition and Changes in Anxiety and Depressive Symptoms From Adolescence to Adulthood	43
Physician Suicide and Associated Features—What Defines a Physician?—Reply	43
Enough to Promote Changes to Current Management of Catatonia?	43
Preexisting Neuropsychiatric Conditions and Associated Risk of Severe COVID-19 Infection and Other Acute Respiratory Infections	43
VA/Department of Defense Clinical Practice Guideline for PTSD and ASD	43
Precision Assignment to Psychosocial Interventions for Late-Life Depression	42
Intranasal Oxytocin and Physical Intimacy for Dermatological Wound Healing and Neuroendocrine Stress	42
Studying Harms Is Key to Improving Psychedelic-Assisted Therapy—Participants Call for Changes to Research Landscape	42
Ambient AI and Measurement Bias in Psychiatric Notes—Reply	42
Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis	42
From Static to Dynamic Prediction of Suicide Risk	42
Genetic Liability to Posttraumatic Stress Disorder Symptoms and Its Association With Cardiometabolic and Respiratory Outcomes	42
Integrated Nicotine Replacement and Behavioral Support to Reduce Smoking in Opioid Agonist Therapy	42
Suicidal Ideation and Suicide Attempts After Direct or Indirect Psychotherapy	41
Transdisciplinary Science and Research Training in Psychiatry	41
How Should We Interpret the Association Between Abortion and Mild Psychiatric Illness?	41
Functional vs Structural Cortical Deficit Pattern Biomarkers for Major Depressive Disorder	41
Acupuncture for Combat-Related Posttraumatic Stress Disorder	41
Toward 90-90-90 Goals for Global Mental Health	41
Implementing Precision Medicine in Psychiatry	40
Complex Interaction of Lithium With Kidney and Bone Health	40
JAMA Psychiatry	40
Considerations Regarding Antipsychotic Drug Prescriptions Among People With Dementia During the COVID-19 Pandemic	40
Antipsychotic Monotherapy vs Polytherapy for Pneumonia Risk—Reply	40
Combination Antidepressant Therapy vs Monotherapy—Further Considerations—Reply	40
Potential of Control Conditions for Nonspecific Treatment-Effects in Noninferiority Trials—Reply	40
JAMA Psychiatry	40
Informant Effect on Placebo Response in Mental Disorders—Reply	39
Error in Figure 1	39
Error in Figure	38
Development of Major Depressive Disorder—Does Insulin Resistance Play a Role?—Reply	38
Short-Term Trials Underestimate Antidepressant Withdrawal—Reply	38
Investing in a Research Workforce With Personal Experience of Serious Mental Illness	37
Functional Connectivity of the Nucleus Accumbens and Changes in Appetite in Patients With Depression	37
Interpretation of the HAMLETT Study	37
Effect of Technology-Enhanced Screening in Addition to Standard Targeted Clinician Education on the Duration of Untreated Psychosis	36
RETRACTED: Dynamic Prediction of Outcomes for Youth at Clinical High Risk for Psychosis	36
Association of Cardiovascular Health With Risk of Clinically Relevant Depressive Symptoms	36

Why Hippocampal Glutamate Levels Are Elevated in Schizophrenia	36
Understanding Placebo Mechanisms to Reduce Attrition in Psychiatric Trials	36
Female Physician Suicide Compared to the General Population	36
Issues With Person-Time and Repetitive Event Calculation	36
Results of the First European Board Examination in Psychiatry	36
Effects of a Smartphone-Based Self-management Intervention for Individuals With Bipolar Disorder on Relapse, Symptom Burden, and Quality of Life	35
Prescription Stimulant Prescribing, Nonmedical Use, and Shortages	35
Psilocybin in Bipolar II Study Provides Preliminary Data on Safety	35
Mental Health Treatment Gap—The Implementation Problem as a Research Problem	35
Stimulant Use Disorder Diagnoses in Adolescent and Young Adult Medicaid Enrollees	35
Processing Speed Impairment in Schizophrenia	34
Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder	34
Associations Between Early Life Adversity, Reproduction-Oriented Life Strategy, and Borderline Personality Disorder	34
Brain Morphometry Normative Modeling—Omit Global Thickness—Reply	34
Written Exposure Therapy vs Prolonged Exposure Therapy in the Treatment of Posttraumatic Stress Disorder	33
COVID-19 and Risk for Mental Disorders Among Adults in Denmark	33
Mental Health Care Support in Rural India	33
Telehealth Mindfulness-Oriented Recovery Enhancement vs Usual Care in Individuals With Opioid Use Disorder and Pain	33
Heart Rate Variability Biofeedback for Substance Use Disorder	33
Coding Error for the Sex Variable in a Meta-analysis	33
Differences in Insurance Coverage for Individuals With Schizophrenia After Implementation of the Patient Protection and Affordable Care Act	33
Substance Use Disorder and Health Outcomes in COVID-19—The Need for a Better Research Method to Determine Substance Use Exposure—Reply	33
Over-the-Counter Naltrexone to Address Unhealthy Alcohol Use	32
Issues With Person-Time and Repetitive Event Calculation—Reply	32
Antipsychotic Acute-Phase Treatment in Individuals With and Without Recent Treatment	32
COP27 Climate Change Conference—Urgent Action Needed for Africa and the World	32
Change Patterns of Posttraumatic and Grief Disorders and Their Somatic Variables in Ongoing Trauma	32
Substance Use Disorder and Health Outcomes in COVID-19—The Need for a Better Research Method to Determine Substance Use Exposure	32
Posttraumatic Stress Disorder, Obesity, and Accelerated Epigenetic Aging Among US Military Veterans	31
Depression Associated With Hormonal Contraceptive Use as a Risk Indicator for Postpartum Depression	31
Change to Open Access Status	31
Lessons Learned From Drug Decriminalization Remedies in British Columbia	31
Cannabis Use Among Individuals With Psychosis After State-Level Commercial Cannabis Legalization	31
Alcohol Cue Processing in Co-Occurring Bipolar Disorder and Alcohol Use Disorder	31
Association of Oxidative Stress–Induced Nucleic Acid Damage With Psychiatric Disorders in Adults	31
Preaddiction—A Missing Concept for Treating Substance Use Disorders	30
Estimated Number of Children Who Lost a Parent to Drug Overdose in the US From 2011 to 2021	30
Data-Driven Contingency Management Incentive Magnitudes	30
Transcriptome-Wide Structural Equation Modeling of 13 Major Psychiatric Disorders for Cross-Disorder Risk and Drug Repurposing	30
A Ketogenic Diet for Treatment-Resistant Depression	30
Mental Disorders as Homeostatic Property Clusters	29
International Variation in Clozapine Hematologic Monitoring—A Call for Action	29
Timing of Antidepressant Discontinuation During Pregnancy and Postpartum Psychiatric Outcomes in Denmark and Norway	29
Distinct Convergent Brain Alterations in Sleep Disorders and Sleep Deprivation	28
Inflammatory Exposure and Depression in Older Adults With Insomnia	28
From Schedule I to the Clinic—Insights Into Psychedelic Drug Development From GHB	28
Patterns of Brain Maturation in Autism and Their Molecular Associations	28
Reporting and Representation of Race and Ethnicity in Clinical Trials of Pharmacotherapy for Mental Disorders	28
Value-Based Payment and Behavioral Health	27
Association of 24-Hour Activity Pattern Phenotypes With Depression Symptoms and Cognitive Performance in Aging	27
Suicidality Calls to a National Helpline After a Terror Attack and War	27
Artificial Intelligence and the Potential Transformation of Mental Health	27
JAMA Psychiatry Editorial Fellow	27
Effectiveness of Standard Sequential Bilateral Repetitive Transcranial Magnetic Stimulation vs Bilateral Theta Burst Stimulation in Older Adults With Depression	27
Notice of Retraction: Worthington MA et al. Dynamic Prediction of Outcomes for Youth at Clinical High Risk for Psychosis: A Joint Modeling Approach. JAMA Psychiatry.	26
Evolutionary Inquiries Into the Origin and Nature of Mental Disorders	26
Clinician Suicide Risk Assessment for Prediction of Suicide Attempt in a Large Health Care System	26
Social Disconnection as a Global Behavioral Epidemic—A Call to Action About a Major Health Risk Factor	26
Penetrance and Pleiotropy of Polygenic Risk Scores for Schizophrenia, Bipolar Disorder, and Depression Among Adults in the US Veterans Affairs Health Care System	26
Clozapine After 1 Failed Antipsychotic Drug Trial in First-Episode Psychosis	25
Mental Health Service Use Before First Diagnosis of a Psychotic Disorder	25
Comorbid Depression in Atopic Dermatitis—The Itch-to-Brain Circuitry Theory	25
Treatment Outcomes With Licensed and Unlicensed Stimulant Doses for Adults With Attention-Deficit/Hyperactivity Disorder	25
Cognitive Function in People With Familial Risk of Depression	25
Change to Open Access Status	25
Antipsychotic Medications and Mortality in Children and Young Adults	25
Clinical Outcomes of Magnetic Seizure Therapy vs Electroconvulsive Therapy for Major Depressive Episode	25
Error in Figure 2	25
Antidepressant Use and Manic Episodes in Children and Adolescents With Unipolar Depression	24
Error in Figure Caption	24
JAMA Psychiatry	24
Parental Mental Disorders and Offspring Mortality up to Middle Age	24
Targeting Biomarkers and the FDA’s Biomarker Qualification Framework	24
SSRIs in Pregnancy—What Offspring Brain Volumes Can and Cannot Tell Us—Reply	24
Nationwide Transdiagnostic Age and Sex Patterns in Mental Disorder Disease Development	24
Preliminary Research Priorities for Factors Influencing Individual Outcomes for Users of the US National Suicide Prevention Lifeline	24
Error in Display of Author Name	24
Errors in Network Meta-Analysis of Generalized Anxiety Disorder Psychotherapies	24
Trends in Medicaid Utilization and Financing for Hospitals With Psychiatric Beds	23
National Data on Age Gradients in Well-being Among US Adults	23
Potential of Control Conditions for Nonspecific Treatment Effects in Noninferiority Trials	23
Grief-Specific Cognitive Behavioral Therapy vs Present-Centered Therapy	23
Years of Life Lost to Drug Overdose Among Black Female Individuals in the US, 2015-2021	23
Climate Events, Displacement, and Mental Health—Uprooted	23
Gratitude and Mortality Among Older US Female Nurses	22
The Year in Review, 2025	22
Sleep Abnormalities in Different Clinical Stages of Psychosis	22
Addressing the Escalating Problems That Patients Encounter When Filling Buprenorphine Prescriptions	22
Anorexia Nervosa—Facts, Frustrations, and the Future	22
Author Name Change	22
Efficacy of Adjunctive D-Cycloserine to Intermittent Theta-Burst Stimulation for Major Depressive Disorder	22
Transmission of Mental Disorders in Adolescent Peer Networks	22
Error in Results	22
Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression	22
Promoting Social Prescribing in Psychiatry—Using Shared Decision-Making and Peer Support	22